ArticleInternational journal of general medicine2026
Identification and Validation of FOXK1-Related Biomarkers in Diabetic Retinopathy.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is a leading cause of irreversible blindness globally. Analysis of dataset GSE221521 showed significant upregulation of FOXK1 in DR patient blood. Functional studies indicated that silencing FOXK1 promotes endothelial cell apoptosis, migration, and neovascularization under high glucose via the p-AKT/AKT pathway, suggesting FOXK1 plays a key role in DR. This study aims to identify FOXK1-related biomarkers in DR. Methods: We integrated two DR-related datasets (GSE221521 and GSE189005). Candidate genes were identified through differential expression analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Biomarkers were subsequently screened using the Least Absolute Shrinkage and Selection Operator (LASSO) regression and validated based on their expression profiles. Further analyses included immune infiltration assessment, construction of a regulatory network, Gene Set Enrichment Analysis (GSEA), protein-protein interaction analysis via GeneMANIA, and drug prediction. The expression of key biomarkers was experimentally confirmed using reverse transcription quantitative polymerase chain reaction (RT-qPCR) on clinical peripheral blood samples. Results: From seven initial candidate genes, SPDEF and SLC25A41 were validated as diagnostic biomarkers. A predictive nomogram constructed with these biomarkers showed significant prognostic value. Immune infiltration analysis revealed significantly higher levels of Macrophages M0, monocytes, and activated CD4 memory T cells in DR samples. The constructed TF-miRNA-mRNA network included 10 transcription factors and 2 microRNAs, with FOXC1 and hsa-mir-335-5p co-regulating both SPDEF and SLC25A41. GSEA identified 74 associated pathways, including oxidative phosphorylation. Drug prediction suggested 25 potential targeting compounds, with resveratrol, daunorubicin, and digitoxigenin emerging as promising candidates. Finally, RT-qPCR analysis confirmed the significant downregulation of both SPDEF and SLC25A41 in DR patients, consistent with the bioinformatics findings. Conclusion: Our findings suggest that SPDEF and SLC25A41 serve as potential biomarkers for DR, which may aid in early detection and provide new insights into the pathogenesis of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.